Agreed, Dr_Lowenstein has been right all along on the significance of the data because of the size of this trial. I have been appreciative of his posts and his way of analyzing things and statements. I personally do not think he is short btw; I think he just doesn't like unsubstantiated claims/statements, which is good if you want to be a better investor.
In case you missed it, he also sees a signal from this interim data, and feels there need to be more patients enrolled in order for this trial to be conclusive. Accordingly, ONCS is also working with the FDA to modify current trial protocol. What investors need to do is temper their expectations and invest only what they can afford to lose in the near term. I've seen deals being made at preclinical/proof of concept stages, so I don't think ONCS's trial size is a red flag by any means. There just needs to be a balance between paradigm shifting thoughts and doomsday arguments, if you want to make a rational investment decision with any biotech stock.
News 
Market Data 
Discover 
AI
